You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

Displaying 196051 - 196060 of 207712 results
  1. TOPIC 296 PHASE II; UNIFIED PLATFORM FOR MANAGING OBJECTIVE BEHAVIORAL DATA; HHSN

    SBC: MEI Research, Ltd            Topic: NCI

    Unified Platform for Managing Objective Behavioral Data PUBLIC HEALTH RELEVANCE

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  2. TOPIC 324 PHASE I 9 MONTH FUNDING; NOVEL IMAGING AGENTS T EXPAND TE CLINICAL TOOL

    SBC: ROCKLAND IMMUNOCHEMICALS, INC.            Topic: NCI

    Medical imaging and targeted therapy are the central components in the clinical management of cancer patients. Rockland Immunochemicals, Inc. is teaming up with Abzyme Therapeutics LLC to develop novel imaging agents that can be used in both cancer diagnosis and targeted therapy. In this phase I proposal, high-affinity camelid single domain antibodies to three cancer biomarkers HER2, EGFR and meso ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  3. TOPIC 324 PHASE I; NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOL KIT FOR CANCE

    SBC: EVORX TECHNOLOGIES, INC.            Topic: NCI

    Targeted molecular imaging of cancer is vital for better personalized medicine, but requires novel imaging agents that recognize key molecular surface cell markers. Her2 is overexpressed in 20-30% of breast cancer and is targeted by Herceptin, yet no molecular imaging agent for Her2 is clinically approved. We propose to use Scanning Unnatural Protease Resistant (SUPR) peptides to develop a novel H ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  4. TOPIC 324 PHASE I NOVEL IMAGING AGENTS TO EXPAND THE CLINICAL TOOLKIT FOR CANCER

    SBC: INNOSENSE CORPORATION            Topic: NCI

    This project aims to demonstrate the feasibility of an in vivo diagnostic platform for recognizing indicators of tumor-microenvironment, unambiguously, in biological fluids, tissue phantoms and small animal imaging. Specific project aims are to synthesizeand evaluate cancer-specific, thermoresponsive, nanoparticle-based, near-infrared (NIR) fluorescent contrast agents (ThermoDots) for optical imag ...

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  5. TOPIC 316 PHASE I: OMICS CHIPS FOR CTC ISOLATION AND MOLECULARY ANALYSIS; HHSN261

    SBC: NEWOMICS INC.            Topic: NCI

    Not Available

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  6. TOPIC 319 PHASE I; RECOMBINANT RABBIT MONOCLONAL ANTIBODIES AS AFFINITY CAPTURES

    SBC: AVANTGEN INC            Topic: NCI

    Recombinant rabbit monoclonal antibodies as affinity captures for peptides PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  7. TOPIC 313 PHASE I; RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY; HHSN2612013000

    SBC: GENESEGUES INC            Topic: NCI

    The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer. PUBLIC HEALTH RELEVANCE

    SBIR Phase I 2013 Department of Health and Human ServicesNational Institutes of Health
  8. TOPIC 313 PHASE I; RNAI CANCER THERAPEUTICS USING NANOTECHNOLOGY; HHSN2612013000

    SBC: GENESEGUES INC            Topic: N/A

    The design, fabrication, characterization, and preclinical evaluation of novel nanoparticle-based drug formulations capable of delivering candidate RNAi therapeutics for the treatment of cancer.

    SBIR Phase II 2014 Department of Health and Human ServicesNational Institutes of Health
  9. TOPIC #411- PHASE I SBIR CONTRACT- AN IMAGEDX BASED PLATFORM FOR COMPREHENSIVE DE-IDENTIFICATION OF WSI DATA

    SBC: REVEAL BIOSCIENCES, INC.            Topic: 37

    The objective of this proposal is to develop a de-identification tool capable of ensuring adherence of whole slide imaging (WSI) data from multiple vendors to the HIPAA Privacy Rule. Such a de-identification tool will be used to more efficiently and comprehensively de-identify the large data stores required by commercial and government funded researchers. Deidentification will be developed as the ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
  10. TOPIC #411- PHASE I SBIR CONTRACT- DE-IDENTIFICATION SOFTWARE TOOLS FOR CANCER IMAGING RESEARCH

    SBC: BIODATA CONSORTIUM, LLC            Topic: 411

    Developing artificial intelligence technology for medical imaging applications requires training models on large and diverse datasets. Currently, aggregation of large data repositories, including radiology and pathology images, is limited by concerns around patient privacy. In order to successfully share medical images, an institution must be able to quickly and accurately de-identify large number ...

    SBIR Phase I 2020 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government